The definitive agreement, signed August 16, 2026, marks a strategic retreat from European markets. Under the terms, IM Cannabis will reorganize its structure to retain its core Israeli medical cannabis operations while transferring entities like Adjupharm GmbH and Xinteza API Ltd. to Slil.com Holding Ltd. The buyer will assume liabilities capped at 9.4 million Canadian dollars, effectively clearing those obligations from the parent company’s books.
IM Cannabis to Shed European Assets in Related-Party Sale
Conflict lead: Facing severe financial strain, IM Cannabis Corp. has agreed to sell its subsidiary, IMC Holdings, to a firm controlled by its own CEO, Oren Shuster. The deal aims to stabilize the company’s balance sheet by offloading international debt in exchange for a projected 3 million Canadian dollar equity boost.
Because the transaction involves CEO Oren Shuster, it qualifies as a related-party deal under Canadian securities regulations. To bypass the standard requirements for minority shareholder approval and formal valuations, the company is invoking a financial hardship exemption. The board maintains that this expedited sale is necessary to address the company’s liquidity issues and debt obligations. While no formal valuation is required, the company has commissioned Beta Finance T.Y.S Ltd. to provide a fairness analysis. The transaction is slated to close by September 30, 2026.
Comments (0)
No comments yet. Be the first!